A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630

PURPOSE: The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may enhance antitumor effects. We conducted an open-label randomized phase II/III study to evaluate nivolumab + docetaxel combination therapy in comparison with nivolumab monotherapy for previously treated ICI-naïve...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Yuri, Shimokawa, Tsuneo, Takiguchi, Yuichi, Misumi, Toshihiro, Nakamura, Yukiko, Kawashima, Yosuke, Furuya, Naoki, Shiraishi, Yoshimasa, Harada, Toshiyuki, Tanaka, Hisashi, Miura, Satoru, Uchiyama, Ayumi, Nakahara, Yoshiro, Tokito, Takaaki, Naoki, Katsuhiko, Bessho, Akihiro, Goto, Yasuhiro, Seike, Masahiro, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561604/
https://www.ncbi.nlm.nih.gov/pubmed/35980349
http://dx.doi.org/10.1158/1078-0432.CCR-22-1687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561604/
https://www.ncbi.nlm.nih.gov/pubmed/35980349
http://dx.doi.org/10.1158/1078-0432.CCR-22-1687

Ejemplares similares